Literature DB >> 28240607

Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.

Laure Gilles, Ahmet Dirim Arslan, Christian Marinaccio, Qiang Jeremy Wen, Priyanka Arya, Maureen McNulty, Qiong Yang, Jonathan C Zhao, Katerina Konstantinoff, Terra Lasho, Animesh Pardanani, Brady Stein, Isabelle Plo, Sriram Sundaravel, Amittha Wickrema, Annarita Migliaccio, Sandeep Gurbuxani, William Vainchenker, Leonidas C Platanias, Ayalew Tefferi, John D Crispino.   

Abstract

Primary myelofibrosis (PMF) is a clonal hematologic malignancy characterized by BM fibrosis, extramedullary hematopoiesis, circulating CD34+ cells, splenomegaly, and a propensity to evolve to acute myeloid leukemia. Moreover, the spleen and BM of patients harbor atypical, clustered megakaryocytes, which contribute to the disease by secreting profibrotic cytokines. Here, we have revealed that megakaryocytes in PMF show impaired maturation that is associated with reduced GATA1 protein. In investigating the cause of GATA1 downregulation, our gene-expression study revealed the presence of the RPS14-deficient gene signature, which is associated with defective ribosomal protein function and linked to the erythroid lineage in 5q deletion myelodysplastic syndrome. Surprisingly, reduced GATA1 expression and impaired differentiation were limited to megakaryocytes, consistent with a proproliferative effect of a GATA1 deficiency on this lineage. Importantly, expression of GATA1 effectively rescued maturation of PMF megakaryocytes. Together, these results suggest that ribosomal deficiency contributes to impaired megakaryopoiesis in myeloproliferative neoplasms.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28240607      PMCID: PMC5373858          DOI: 10.1172/JCI82905

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

Authors:  Alessandro Maria Vannucchi; Lucia Bianchi; Cristina Cellai; Francesco Paoletti; Rosa Alba Rana; Rodolfo Lorenzini; Giovanni Migliaccio; Anna Rita Migliaccio
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

2.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.

Authors:  J L Villeval; K Cohen-Solal; M Tulliez; S Giraudier; J Guichard; S A Burstein; E M Cramer; W Vainchenker; F Wendling
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

Authors:  Ruben A Mesa; Xiaopan Yao; Larry D Cripe; Chin Yang Li; Mark Litzow; Elisabeth Paietta; Jacob M Rowe; Ayalew Tefferi; Martin S Tallman
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

5.  Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.

Authors:  Alessandro M Vannucchi; Alessandro Pancrazzi; Paola Guglielmelli; Simonetta Di Lollo; Costanza Bogani; Gianna Baroni; Lucia Bianchi; Anna Rita Migliaccio; Alberto Bosi; Francesco Paoletti
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

6.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Authors:  Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

7.  Genetics. Mysterious ribosomopathies.

Authors:  Kathleen L McCann; Susan J Baserga
Journal:  Science       Date:  2013-08-23       Impact factor: 47.728

8.  Altered translation of GATA1 in Diamond-Blackfan anemia.

Authors:  Leif S Ludwig; Hanna T Gazda; Jennifer C Eng; Stephen W Eichhorn; Prathapan Thiru; Roxanne Ghazvinian; Tracy I George; Jason R Gotlib; Alan H Beggs; Colin A Sieff; Harvey F Lodish; Eric S Lander; Vijay G Sankaran
Journal:  Nat Med       Date:  2014-06-22       Impact factor: 53.440

9.  Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion.

Authors:  Ingmar Bruns; Daniel Lucas; Sandra Pinho; Jalal Ahmed; Michele P Lambert; Yuya Kunisaki; Christoph Scheiermann; Lauren Schiff; Mortimer Poncz; Aviv Bergman; Paul S Frenette
Journal:  Nat Med       Date:  2014-10-19       Impact factor: 53.440

10.  Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Authors:  Qiang Jeremy Wen; Qiong Yang; Benjamin Goldenson; Sébastien Malinge; Terra Lasho; Rebekka K Schneider; Lawrence J Breyfogle; Rachael Schultz; Laure Gilles; Priya Koppikar; Omar Abdel-Wahab; Animesh Pardanani; Brady Stein; Sandeep Gurbuxani; Ann Mullally; Ross L Levine; Ayalew Tefferi; John D Crispino
Journal:  Nat Med       Date:  2015-11-16       Impact factor: 53.440

View more
  26 in total

Review 1.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

Review 2.  Management of Myelofibrosis-Related Cytopenias.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 3.  New Concepts of Treatment for Patients with Myelofibrosis.

Authors:  Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

4.  Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?

Authors:  Richard T Piszczatowski; Ulrich Steidl
Journal:  Clin Cancer Res       Date:  2019-06-13       Impact factor: 12.531

5.  Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice.

Authors:  Orly Leiva; Seng Kah Ng; Shinobu Matsuura; Vipul Chitalia; Hector Lucero; Alison Findlay; Craig Turner; Wolfgang Jarolimek; Katya Ravid
Journal:  Int J Hematol       Date:  2019-10-21       Impact factor: 2.490

6.  Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.

Authors:  Sriram Sundaravel; Wen-Liang Kuo; Jong Jin Jeong; Gaurav S Choudhary; Shanisha Gordon-Mitchell; Hui Liu; Tushar D Bhagat; Kathy L McGraw; Sandeep Gurbuxani; Alan F List; Amit Verma; Amittha Wickrema
Journal:  Clin Cancer Res       Date:  2019-07-15       Impact factor: 12.531

Review 7.  Novel targets to cure primary myelofibrosis from studies on Gata1low mice.

Authors:  Maria Zingariello; Fabrizio Martelli; Paola Verachi; Claudio Bardelli; Francesca Gobbo; Maria Mazzarini; Anna Rita Migliaccio
Journal:  IUBMB Life       Date:  2019-11-21       Impact factor: 3.885

Review 8.  Mechanisms of erythrocyte development and regeneration: implications for regenerative medicine and beyond.

Authors:  Emery H Bresnick; Kyle J Hewitt; Charu Mehta; Sunduz Keles; Robert F Paulson; Kirby D Johnson
Journal:  Development       Date:  2018-01-10       Impact factor: 6.868

9.  A patient with a germline GATA2 mutation and primary myelofibrosis.

Authors:  Cyrill V Rütsche; Eugenia Haralambieva; Veronika Lysenko; Stefan Balabanov; Alexandre P A Theocharides
Journal:  Blood Adv       Date:  2021-02-09

Review 10.  The Role of Megakaryocytes in Myelofibrosis.

Authors:  Johanna Melo-Cardenas; Anna Rita Migliaccio; John D Crispino
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-11       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.